ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Study ID: STU 052018-099
The current phase 3 trial seeks to improve the event-free survival (eFS) for children with high-risk neuroblastoma through early integration of promising novel targeted therapies: targeted radiopharmaceutical therapy with 131i-MiBG or the aLK inhibitor, crizotinib. after enrollment, patients will receive one cycle of induction chemotherapy. Subsequent therapy will be based upon MiBG avidity and aLK status.
Primary aims - To determine in the context of a randomized trial whether the eFS of patients with newly diagnosed high-risk nBL is improved with the addition of 131i-MiBG during induction, prior to tandem autologous stem cell transplantation (aSCT).